Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device

News Data demonstrated a high rate of procedural success and low rate of complications for the device which offers stroke risk reduction for patients with non-valvular atrial fibrillation (AF) who are seeking an alternative to long-term warfarin therapy. Contributed Author: Boston Scientific